There is currently a pandemic of respiratory disease caused by a novel coronavirus (SARS-CoV-2) named “Coronavirus Disease 2019” (COVID-19). SARS-CoV-2 has demonstrated the capability to spread rapidly, leading to significant impacts on healthcare systems and causing societal disruption. The potential public health threat posed by COVID-19 is high, both to the United States and globally. To effectively respond to the COVID-19 outbreak, rapid detection of cases, appropriate clinical management, infection control, and implementation of community mitigation efforts are all critical.
Under the FDA’s Emergency Use Authorization (EUA) for diagnostic testing, Gene-IQ is committed to providing access to COVID-19 testing solutions with high-quality, high-throughput rRT-PCR based assays.